Generic Name and Formulations:
Mesalamine 4g/60mL; enema; contains sulfites.
Mylan Specialty L.P.
Indications for ROWASA:
Mild-to-moderate distal ulcerative colitis, proctosigmoiditis, proctitis.
4g (60mL) daily at bedtime for 3–6 weeks. Retain enema for 8 hours.
Sulfasalazine allergy. Renal dysfunction; monitor urinalysis, BUN, creatinine. Asthma. Pregnancy. Nursing mothers.
Abdominal pain/cramps/discomfort, headache, flatulence, nausea, diarrhea, flu, malaise, fever, sore throat, dizziness, bloating, joint, back, or rectal pain, hemorrhoids, itching, constipation, hair loss, pancolitis, pericarditis, rash; acute intolerance syndrome (discontinue if occurs).
Enema—7, 14, 28
Endocrinology Advisor Articles
- FDA Approves Marketing of 2 Devices to Detect Parathyroid Tissue in Real Time
- Long-Term Efficacy and Safety of Dapagliflozin for Type 1 Diabetes
- Diabetes Education Week 2018: Patient Resources for Your Practice
- Cardiometabolic Disease Patterns Related to Race, Ethnicity in Midlife Women
- AHA, ADA Announce Joint Education Initiative to Reduce CVD Deaths in T2D